1. IV busulfan combined with cyclophosphamide (BuCy) is associated with better leukemia-free and overall survival in acute myeloid leukemia (AML) than total body irradiation (TBI).
2. Improved outcomes and greater ease of administration favor BuCy over Cy/TBI for AML patients in first complete remission (CR) undergoing hematopoietic cell transplantation...
Image: PD AML
1. Rituximab use is linked with a reduction in chronic graft-vs-host disease following peripheral blood stem cell transplantation.
2. Rituximab is also linked with improved survival following transplantation compared to controls.
Evidence Rating Level: 2 (Good)
Study rundown: Following peripheral blood stem cell transplantation, chronic GVHD (graft-vs-host disease) is a...